Our Company

Glycotest is developing unique and non-invasive blood tests for the large populations at risk of developing liver cancers and fibrosis-cirrhosis. Our proprietary technology could revolutionize care and treatment for groups at risk due to chronic liver disease-both people with viral hepatitis (chronic hepatitis B and C infections) and the rapidly growing population with non-viral hepatitis (NASH) due to obesity and metabolic disease. Over 25 million people in the U.S., 800 million worldwide, and another 1.2 billion in jeopardy due to fatty liver disease (NAFLD) may benefit from Glycotest’s products.


Glycotest was created in 2012 based on technology developed by two experts in the fields of liver disease and glycobiology-Professors Timothy Block and Anand Mehta at Drexel University College of Medicine and the Baruch S. Blumberg Institute. Glycotest has the exclusive worldwide rights to the use of over 50 patented serum glycoprotein biomarkers whose sugar structures are altered in liver cancers and fibrosis-cirrhosis by the abnormal attachment of the monosaccharide fucose.

First Test–HCC Panel for Early Detection

Our first test is the HCC Panel which is designed for the early detection of Hepatocellular Carcinoma (HCC). The HCC Panel is a surveillance test for patients who have had chronic liver disease and are at a higher risk of getting HCC. If HCC is detected early, it can be curable, but unfortunately, current test methods are not sensitive enough to catch most early-stage HCC. The HCC Panel test is currently being used in a 476 patient clinical validation study which we expect will be completed in mid-2020. We are planning to launch the HCC Panel to hepatologists late next year through our CLIA lab.



  • Charles Swindell

    Charles Swindell has over 30 years of experience in biopharmaceutical R&D, product development, and senior management in entrepreneurial life science companies.   He has …


  • Professor Stephen Smith

    Professor Stephen Smith, Non-Executive Director, joined the NetScientific Board in 2016. Stephen has held senior leadership roles in the NHS and academia. He has …

  • Ilian Iliev PhD

    Dr. Ilian Iliev joined the Net Scientific Board in 2019 and became CEO in 2020. He is also Managing Director of EMV Capital (EMVC) …

  • Mr Yuejian ZHANG

    Mr Yuejian ZHANG graduated with Ph.D. degree of Immunology from Fudan University in 2000. He joined Shanghai Fosun Pharmaceutical (Group) Co. Ltd. since Sep …

  • Mr Jing YU

    Mr Jing YU holds a Ph.D. degree of Pharmaco-economy. He had served as researcher for various national medical and healthcare institutes and organizations during …



NetScientific UK Ltd.

About NetScientific UK Ltd.

About NetScientific UK Ltd.

NetScientific identifies, develops and commercializes transformative biomedical and healthcare technologies originating from leading universities, teaching hospitals and research institutes, with a focus on United Kingdom and United States.

More information about NetScientific’s purpose, core strategy and investment model are available at netscientific.net.

Fosun Pharma

About Fosun Pharma

About Fosun Pharma

Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare group in the PRC. Adhering to the mission of improving human health, Fosun Pharma’s business covers all key sectors of the healthcare industry chain, including pharmaceutical manufacturing and R&D, healthcare services, medical devices, and medical diagnosis, as well as pharmaceutical distribution and retail. Fosun Pharma always regards innovation as the driving force for its business growth.

More information about Fosun Pharma click: https://www.fosunpharma.com


A New Paradigm for Early Diagnosis and Surveillance For Liver Cancer

ABOUT US | Glycotest Diagnostics